Objectives: To assess which vasopressin receptor subtype mediates the vasodilation occurring in response to arginine vasopressin and 1-desamino-8-D (DD)-argtnine vasopressin and whether nitric oxide is involved in these effects.
Introduction owes its two names to its main functions: vaso-' ----------------------------------------------""
constriction and antidiuresis. Vasopressin type 1 (V \) The neurohypophyseal hormone arginine vasopressin, receptors on vascular smooth muscle cells mediate the which is also referred to as the antidiuretic hormone, vasoconstrictive action, whereas vasopressin type 2 (V2)
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Journal of Hypertension 1995, Vol 1 3 No 1 2 (part 2) receptors are involved in the antidiuretic effect exerted in renal collecting duct cells. A less well-known effect o f arginine vasopressin is vasodilation, which has been found to occur in response to high local concentrations o f the horm one [1] [2] [3] [4] [5] . Attempts to assess the type of receptor mediating this va so dilatory action have yielded contradictory results, with discrepancies between in i>u>o and in vitro studies, among diflerent species and among vascular beds [6] [7] [8] . h i vivo studies using Vj receptor antagonists have indicated that the vasodilation occur ring in response to high doses of arginine vasopressin is mediated by Vo receptors [1, 3, [9] [10] [11] [12] [13] , an observation w hich is in accord with the vasodilatory effect of the V 2 receptor agonist l-desam ino-8 -U (DD)-arginine vasopressin [1] , Furthermore, recent investigations have suggested a role for endothelium-derived nitric oxide in the vasodilator response to arginine vasopressin [4, [14] [15] [16] [17] .
In the present study, we assessed in human forearm vasculature which vasopressin receptor subtype mediates arginine vasopressin-and D D -arginine vasopressininduced vasodilation by comparing the responses of healthy subjects with those o f patients with a proven V2 receptor defect and w hether nitric oxide is involved in arginine vasopressin-and DD-arginine vasopressininduced vasodilation.
M a t e r ia ls a n d m e th o d s
Subjects
T he study protocol was approved by the local ethical com m ittee o f the University Hospital Nijmegen. All subjects gave w ritten informed consent.
Fifteen healthy male volunteers (aged 19-31 years) and three male patients with congenital nephrogenic diabetes insipidus (aged 21-30 years) participated in the study. All o f the nephrogenic diabetes insipidus patients had had polyuria and polydipsia since early childhood and showed no antidiuretic response to DD-arginine vasopressin. In the three patients, D N A sequencing analysis o f the receptor gene had been performed as described previously [18] . In all of the patients, point mutations had been detected in this gene, resulting in ammo acid substitutions in two o f them (phenylalanine 44 to leucine and arginine 202 to cysteine, respectively) and introduction o f a premature stop codon in the third pa:ient (arginine 337 to stop codon).
A physical examination and electrocardiography revealed no abnormalities in any o f the participants. The experiments were perform ed after overnight fasting by the subjects. D uring the 24 h preceding the experiment, they did not smoke or drink beverages containing caffeine or alcohol. In the 2 weeks preceding the study none o f the healthy volunteers had taken any medication. One o f the diabetes patients complied with a request to stop taking hydrochlorothiazide, amiloride and indomethacin 36 h before the start of the experiment, and one patient, who was taking hydrochlorothiazide and amiloride, continued using the medication. The third patient was not taking any medication.
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Study design
The brachial artery of the left arm was cannula ted, The experiments started after an equilibration period of 30 min. Forearm blood flow o f both arms was measured by venous occlusion mercury-in-silastic strain gauge plethysmography Simultaneously, circulation o f the hand was arrested by inflating a cuff around the wrist. The forearm blood flow values obtained during the last 2 min of each infusion were used for further analysis. Blood pressure and heart rate were recorded intra-arterially (Hewlett-Packard Gm bH, Böblingen, Germany).
Protocols were designed to assess the vascular response of DD-arginine vasopressin and arginine vasopressin in healthy subjects; the vascular response to DD-arginine vasopressin and arginine vasopressin in nephrogenic diabetes insipidus patients with a VS receptor defect; and the effect o f L-A/G-monomethy 1-arginine (l-NM M A) on DD-arginine vasopressin-and arginine vasopressininduced vasodilation. One healthy subject and one nephrogenic diabetes insipidus patient participated in both the DD-arginine vasopressin and the arginine vasopressin experiment. 
Statistical analysis
Paired student's t-tests were used to evaluate the effect of L-NMMA 011 baseline forearm blood flow and, by comparison o f changes in forearm blood flow from baseline, the effect o f L-NMMA on DD-arginine vasopressin-induced vasodilation.
Results
Effects of DD-arginine vasopressin and arginine vasopressin in healthy subjects
Infusion o f DD-arginine vasopressin at 0.1, 1 and 10 ng/m in per dl had no significant effect at the lowest dose but an increase in forearm blood flow occurred at the two higher doses (from 1.6 ±0.5 during saline infusion to 7.9 ±2.5 m l/m in per dl at the highest dose; n = 3). Doses o f DD-arginine vasopressin at 5, 10 and 20 ng/m in per dl administered to seven healthy subjects produced a dose-related increase in forearm blood flow ( Table 1 ; Fig. 1 ). Table 1 . Forearm blood flow response of healthy subjects to intraarterial infusion of different doses of 1-desamino-S-D-arginine vaso pressin (n = 7). Forearm blood flow (ml/min/dl) N one o f the studies showed significant changes in blood pressure, heart rate or forearm blood flow in the contralateral arm.
Discussion
Studies assessing the vaso dilatory mechanism of arginine vasopressin and its analogue DD-arginine vasopressin have yielded conflicting data. In vitro experiments in canine cerebral vessels and rat pulmonary artery and aorta suggested involvement o f Vj receptors [15,16.19] , Similarly, in hum an in vitro studies, argi nine vasopressin-induced vasodilation o f cerebral and mesenterial arteries was found to be independent of Vo receptor stimulation [19, 20] . However, most in vivo studies provide evidence that Vo receptors are involved in arginine vasopressin-and D D -arginine vasopressininduced vasodilation [1, 3, 5, [9] [10] [11] [12] [13] . Furthermore, it has been postulated that the vasodilation and associated release o f coagulation and fibrinolysis factors occurring in response to arginine vasopressin and DD-arginine vasopressin administration is neither mediated by V \ nor by V2 receptors because studies in rat aortae and in conscious dogs have revealed an absence o f inhibition both by V] and by Vo antagonists [22, 23] . T he most plausible reason for this confusion seems to be the variability in the pharmacological profile of agonists and/or antagonists that has been suggested to exist among species, between in vitro and in vivo studies and among different vascular beds [6] [7] [8] .
Hum an in vivo studies assessing the effect of high systemic doses of arginine vasopressin are scarce because of the risk of severe vasoconstriction. However, it is clear that no substantial increase in blood pressure occurs despite maintenance of high plasma arginine vasopressin levels [24] . The vascular effects of Vo receptor antagonists have only recently been examined in a human in vivo study, which appeared to confirm that in the hum an forearm V 2 receptors are involved in the vasodilatory effect of arginine vasopressin [5] . However, these conclusions need to be considered with caution, because most V2 receptor antagonists show partial Vj receptor antagonism and their putative specificity has been based mainly on their aquaretic potencies in animals [6] [7] [8] . However, studies in patients with X-linked nephrogenic diabetes insipidus have provided convincing evidence for involvement of the V2 receptor in the vasodilatory actions of DD-arginine vasopressin [25] . As a result of mutations in the V2 receptor gene, patients with nephrogenic diabetes insipidus lack the renal antidiuretic response to DD-arginine vasopressin [26] , In addition, these patients show no vasodilatory, coagulation or fibrinolytic responses to DD-arginine vasopressin, indicating that these extrarenal effects are normally mediated either by an extrarenal Vo receptor encoded by the same gene or by the renal V2 receptor, In the present study we circumvented the restrictions imposed by the side effects o f high systemic doses of arginine vasopressin and DD-arginine vasopressin and the problems caused by lack of specificity of V2 receptor antagonists, by studying the vascular effects of arginine vasopressin and DD-arginine vasopressin in the human forearm both of healthy subjects and of patients with a proven V2 receptor gene defect. The absence of vasodilation during administration of DD-arginine vasopressin and high doses of arginine vasopressin in nephrogenic diabetes insipidus patients proves that both effects are mediated by the receptor encoded by the V 2 receptor gene, excluding the occurrence of non-specific vasodilatory effects or actions mediated by other receptors, for instance the V \ or oxytocin receptor. In addition, it shows that the high selectivity of DD-arginine vasopressin for the renal V2 receptor also applies to the extrarenal Vo receptor. Moreover, the present study unequivocally proves that the absence of extrarenal response to DD-arginine vasopressin in patients with X-linked nephrogenic diabetes insipidus is a direct consequence of an extrarenal V2 receptor defect and is neither caused nor influenced by their renal V2 receptor defect.
As in studies seeking the receptor involved in argi nine vasopressin-and DD-arginine vasopressin-induced vasodilation, attempts to determine which vasodilatory substance mediates this action have produced varying results. In vitro studies in canine cerebral vessels and rat aortae have suggested that nitric oxide causes these effects [14] [15] [16] . However, Russ and colleagues [14, 27] observed only partial inhibition of arginine vasopressin-induced vasodilation by high doses of nitric oxide synthase inhibitors in rat lungs and provided evidence against involvement o f prostaglandins and hyper polarizad on o f vascular smooth muscle. Moreover, in their in vitro study o f human cerebral and mesenterial arteries, Martinez ct al. [20, 21] found that release of nitric oxide in these vessels accounts neither for arginine vasopressin-nor for DD-arginine vasopressin-induced vasodilation.
It has been shown that the counter-regulation ob served in healthy humans after systemic administration of high doses of arginine vasopressin is abolished by indomethacin, suggesting that prostaglandins are involved in its vasodilatory effect [28] . In contrast, studies of arginine vasopressin-induced vasodilation in the human forearm by Suzuki ct ciL [2] suggested that prostaglandins are not involved while experiments by Tagawa ct al [4] strongly implied the involvement of nitric oxide. Hasunuma ct al. [29] found that vasodi lation after systemic DD-arginine vasopressin infusion was not influenced by indomethacin or propranolol administration; however, they did observe an increase in urinary 6 -keto prostaglandin F |a . We observed that the L-NMMA-induced reduction in DD-arginine vasopressin response, if any, was rather small, whereas the current data show, in accord with the findings by Tagawa ct aL [4] , that L-NM M A inhibited arginine vasopressin-induced vasodilation almost completely How can these observations be reconciled with the conclusion that arginine vasopressin and DD-arginine vasopressin both cause vasodilation by stimulating the V2 receptor? Since DD-arginine vasopressin elicited a threefold stronger increase in forearm blood flow than arginine vasopressin did, the present L-NMMA dose of 0.1 m g/m in per dl might not have been sufficient to compete with the quantity of nitric oxide released by DD-arginine vasopressin, whereas it is adequate in the case of arginine vasopressin. However, even with DD-arginine vasopressin at 5 ng/m in per dl, the inhibition was not complete and did not clearly decrease with higher doses of DD-arginine vasopressin.
A more plausible explanation is based on the fact that arginine vasopressin interacts with both Vi and V2 receptors. The V] receptor pathway could, for instance, attenuate an L-NMMA-insensitive vasodilatory compo nent of the V2 receptor pathway. Another possibility is that arginine vasopressin, because of a possible lower availability or affinity for the V2 receptor, initiates only the nitric oxide-dependent mechanisms, whereas DD-arginine vasopressin is capable of inducing an additional L-NMMA-insensitive pathway [30] , Insight into these mechanisms might be increased by the discovery o f the exact location o f the extrarenal V2 receptor. Although physiological evidence has now been obtained that these receptors exist in the human forearm, radioligand binding studies have not been able to confirm their presence in endothelial or vascular smooth muscle cells [31] . However, blood cells, especially monocytes, are a likely location [32, 33] , Furthermore, although the present study shows that extrarenal V2 receptors are the product o f the same gene as renal V2 receptors, the possibility cannot be excluded that, as a result o f alternative splicing, there is some heterogeneity among receptors encoded by the Vo receptor gene, as recently shown to be the case in the kidney [3 4 ]. Further research awaits the detection of extrarenal gene expression o f this gene at the messenger R N A or protein level.
The present study proves that extrarenal Y 2 receptors in the hum an forearm m ediate the vasodilation induced by DD-arginine vasopressin and high doses o f arginine vasopressin, whereas these receptors are not necessary for arginine vasopressin-induced vasoconstriction. Secondly, DD-arginine vasopressin-induced vasodilation seems to be mediated predominantly by a mechanism other than endothelial nitric oxide release, whereas arginine vasopressin-induced vasodilation seems to involve nitric oxide release only. Thus, despite the fact that the same receptor is involved, it appears that the mecha nisms underlying arginine vasopressin-and DD-arginine vasopressin-induced vasodilation are not completely identical.
